Abstract 1146P
Background
About 30-40% of NSCLC patients develop liver metastases during the disease, and liver metastases are the leading cause of death in NSCLC patients. However, the differences in molecular typing of liver metastases in patients with NSCLC remain to be explored. A better understanding of the molecular mechanisms underlying liver metastases from NSCLC may improve clinical treatment.
Methods
A retrospective study of 661 lung cancer patients who underwent clinical treatment and were pathologically confirmed from January 2019 to November 2021 was collected in multiple centers, and the patients were divided into three groups: lung cancer liver metastases only, lung cancer liver metastases combined with metastases from other sites, and lung cancer without liver metastases. Univariate analysis was performed using SPSS version 26.0 to analyze the differences in essential clinical characteristics and driver gene mutation characteristics (EGFR, ALK, KRAS, BRAF, ERBB2, RET), TMB levels, and PD-L1 expression among the three groups.
Results
There was a statistically significant difference in TMB levels among the three groups (p=0.023). Low TMB was less prone to liver metastases, while medium TMB was more likely to develop isolated liver metastases. For driver genes, there was no significant difference between the three groups (p=0.156). Further subgroup analysis showed that KRAS had different mutation sites (G12A, G12C, G12D, G12V) was statistically significant (p=0.039), while different EGFR mutation sites (L858R, T790M, G719X, exon19del, exon20ins) were not associated with liver metastasis (p=0.716). Different PD-L1 levels had almost the same tendency to develop liver metastases (p=0.089). In addition, no history of hepatitis B (p=0.003), resection of primary lung tumor (p<0.001), use of TKI preparations (p=0.005), and anti-angiogenic drugs (p=0.009) of patients with NSCLC were less prone to liver metastases.
Conclusions
There is a specific correlation between different molecular statuses and non-small cell liver metastasis tendency. Applying the correlation between molecular status and metastasis tendency to the clinic can identify patients with liver metastasis tendency earlier and more accurately intervene early.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yajuan Zhang.
Funding
The First Affiliated Hospital of Xi'an Jiaotong University.
Disclosure
All authors have declared no conflicts of interest.